Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Clinical Pharmacology and Therapeutics
|
November 14, 2008
Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9
C Sachse-Seeboth, J Pfeil, D Sehrt, et al.
AAPS Pharmsci
|
December 14, 2001
CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting
S McElroy, C Sachse, J Brockmoller, et al.
Psychopharmacology
|
October 21, 2000
Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients
M Dettling, C Sachse, J Brockmöller, et al.
Rheumatology International
|
April 25, 2000
Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group
T Witte, K Hartung, C Sachse, et al.
Rheumatology International
|
January 1, 1995
Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group
C Sachse, K Lüthke, K Hartung, et al.
Rheumatology International
|
October 23, 1998
Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group
T Witte, K Hartung, T Matthias, et al.
Rheumatology International
|
January 29, 2000
Thrombomodulin in systemic lupus erythematosus: association with clinical and laboratory parameters
T Witte, K Hartung, C Sachse, et al.
Rheumatology International
|
December 2, 1998
IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group
T Witte, K Hartung, C Sachse, et al.
Clinical Pharmacology and Therapeutics
|
September 8, 2015
Heritability of metoprolol and torsemide pharmacokinetics
J Matthaei, J Brockmöller, M V Tzvetkov, et al.
British Journal of Clinical Pharmacology
|
October 6, 1999
Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation
K J Aitchison, J Munro, P Wright, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Clinical Pharmacology and Therapeutics
|
November 14, 2008
Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9
C Sachse-Seeboth, J Pfeil, D Sehrt, et al.
AAPS Pharmsci
|
December 14, 2001
CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting
S McElroy, C Sachse, J Brockmoller, et al.
Psychopharmacology
|
October 21, 2000
Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients
M Dettling, C Sachse, J Brockmöller, et al.
Rheumatology International
|
April 25, 2000
Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group
T Witte, K Hartung, C Sachse, et al.
Rheumatology International
|
January 1, 1995
Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group
C Sachse, K Lüthke, K Hartung, et al.
Rheumatology International
|
October 23, 1998
Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group
T Witte, K Hartung, T Matthias, et al.
Rheumatology International
|
January 29, 2000
Thrombomodulin in systemic lupus erythematosus: association with clinical and laboratory parameters
T Witte, K Hartung, C Sachse, et al.
Rheumatology International
|
December 2, 1998
IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group
T Witte, K Hartung, C Sachse, et al.
Clinical Pharmacology and Therapeutics
|
September 8, 2015
Heritability of metoprolol and torsemide pharmacokinetics
J Matthaei, J Brockmöller, M V Tzvetkov, et al.
British Journal of Clinical Pharmacology
|
October 6, 1999
Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation
K J Aitchison, J Munro, P Wright, et al.
Page
of 5